Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14988410 | 1.00 | SLC7A11 (0.57) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL29697114 | 0.99 | SLC7A11 (0.58) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL15120171 | 0.99 | SLC7A11 (0.58) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL18044209 | 0.99 | SLC7A11 (0.58) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL14988718 | 0.91 | MEN1 (0.62) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL14988715 | 0.91 | MEN1 (0.62) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL29696999 | 0.90 | MEN1 (0.63) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL18044293 | 0.90 | MEN1 (0.63) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL15120164 | 0.90 | MEN1 (0.63) | SLC7A11MEN1ALDH1A1APPMAPT | |
| SCHEMBL14988411 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| EP-3042658-B1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | UNIV KYOTO (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-2959903-B1 | MEDICINE FOR TREATING EYE DISEASE | UNIV KYOTO (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-9931351-B2 | Method for improving leptin resistance | KYOTO UNIVERSITY (JP) | 2018-04-03 | — | — | US | disclosed |
| US-9782420-B2 | Method for treating eye diseases | KYOTO UNIVERSITY (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3042658-A1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | Kyoto University (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160000810-A1 | Method For Treating Eye Diseases | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2959903-A1 | MEDICINE FOR TREATING EYE DISEASE | Kyoto University (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000810-A1 | Method For Treating Eye Diseases | CFB, AGER, CFH | SLC7A11 1269/4885MEN1 4564/4885ALDH1A1 564/4885 |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | SLC7A11 1464/4885MEN1 2216/4885ALDH1A1 695/4885 |
| US-20160303144-A1 | Medicinal Composition Improving Leptin Resistance | LIPC, ADIPOR1, GPR119 | SLC7A11 3725/4885MEN1 1433/4885ALDH1A1 574/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | SLC7A11 3951/4885MEN1 2693/4885ALDH1A1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.